<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ligand Pharmaceuticals Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated</link>
    <description>Latest news and press releases for Ligand Pharmaceuticals Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ligand-pharmaceuticals-incorporated" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835913e78dffbe2df1025f3.webp</url>
      <title>Ligand Pharmaceuticals Incorporated</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated</link>
    </image>
    <item>
      <title>Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligands-position-as-a-leading-biopharma-royalty-aggregator</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50</description>
    </item>
    <item>
      <title>Ligand to Report First Quarter 2026 Financial Results on May 7, 2026</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United</description>
    </item>
    <item>
      <title>Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs</guid>
      <pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
      <description>FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data</description>
    </item>
    <item>
      <title>Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-advances-strategic-growth-with-expanded-and-strengthened-business-development-team</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare</description>
    </item>
    <item>
      <title>Ligand Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and</description>
    </item>
    <item>
      <title>Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-fourth-quarter-full-120000324</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-fourth-quarter-full-120000324</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. &amp; Canada)(646)</description>
    </item>
    <item>
      <title>Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-present-oppenheimer-36th-annual-healthcare-life-sciences-conference-2026-02-04</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-present-oppenheimer-36th-annual-healthcare-life-sciences-conference-2026-02-04</guid>
      <pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-hosts-2025-investor-day-and-introduces-2026-guidance-2025-12-09</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-hosts-2025-investor-day-and-introduces-2026-guidance-2025-12-09</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of</description>
    </item>
    <item>
      <title>Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-2025-11-06</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-third-quarter-2025-financial-results-and-raises-guidance-2025-11-06</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million</description>
    </item>
    <item>
      <title>Ligand to Participate in November Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-november-investor-conferences-2025-10-30</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-november-investor-conferences-2025-10-30</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025</description>
    </item>
    <item>
      <title>Ligand to Host Investor Day on December 9, 2025</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-host-investor-day-december-9-2025-2025-10-16</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-host-investor-day-december-9-2025-2025-10-16</guid>
      <pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take</description>
    </item>
    <item>
      <title>Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-sq-innovation-receives-fda-approval-lasixr-onyu-home-treatment-edema</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-partner-sq-innovation-receives-fda-approval-lasixr-onyu-home-treatment-edema</guid>
      <pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
      <description>Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th</description>
    </item>
    <item>
      <title>Ligand to Participate in September Investor Conferences</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-september-investor-conferences-2025-08-19</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-participate-september-investor-conferences-2025-08-19</guid>
      <pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis</description>
    </item>
    <item>
      <title>Ligand Announces Closing of Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-closing-convertible-senior-notes-offering-2025-08-14</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-closing-convertible-senior-notes-offering-2025-08-14</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its</description>
    </item>
    <item>
      <title>Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-pricing-400-million-convertible-senior-notes-offering-2025-08-12</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-pricing-400-million-convertible-senior-notes-offering-2025-08-12</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million</description>
    </item>
    <item>
      <title>Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-proposed-offering-400-million-convertible-senior-notes-due-2030-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-announces-proposed-offering-400-million-convertible-senior-notes-due-2030-2025</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0</description>
    </item>
    <item>
      <title>Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-2025-08-07</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-reports-second-quarter-2025-financial-results-and-raises-guidance-2025-08-07</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million</description>
    </item>
    <item>
      <title>Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-and-medtronic-commit-dollar70-million-in-strategic-capital-to-orchestra-biomed-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-and-medtronic-commit-dollar70-million-in-strategic-capital-to-orchestra-biomed-1</guid>
      <pubDate>Thu, 31 Jul 2025 20:01:00 GMT</pubDate>
      <description>• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers</description>
    </item>
    <item>
      <title>Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
      <link>https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-second-quarter-2025-financial-results-august-7-2025-2025-07-24</link>
      <guid isPermaLink="true">https://6ix.com/company/ligand-pharmaceuticals-incorporated/news/ligand-report-second-quarter-2025-financial-results-august-7-2025-2025-07-24</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025</description>
    </item>
  </channel>
</rss>